Samantha Perez-Miller,
Research Associate Scientist
Department:
MD-PHARMACOLOGY / THERAPEUTICS
Business Phone:
(352) 294-5350
Business Email:
perezmiller.s@ufl.edu
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-9034-3693
Publications
2024
Peptide and Peptidomimetic Inhibitors Targeting the Interaction of Collapsin Response Mediator Protein 2 with the N-Type Calcium Channel for Pain Relief.
ACS pharmacology & translational science.
7(7):1916-1936
[DOI] 10.1021/acsptsci.4c00181.
[PMID] 39022365.
2024
Regulating neuronal excitability: The role of S-palmitoylation in NaV1.7 activity and voltage sensitivity.
PNAS nexus.
3(6)
[DOI] 10.1093/pnasnexus/pgae222.
[PMID] 38894876.
2024
Targeted transcriptional upregulation of SENP1 by CRISPR activation enhances deSUMOylation pathways to elicit antinociception in the spinal nerve ligation model of neuropathic pain.
Pain.
165(4):866-883
[DOI] 10.1097/j.pain.0000000000003080.
[PMID] 37862053.
2023
A new polymodal gating model of the proton-activated chloride channel.
PLoS biology.
21(9)
[DOI] 10.1371/journal.pbio.3002309.
[PMID] 37713449.
2023
A peptidomimetic modulator of the CaV2.2 N-type calcium channel for chronic pain.
Proceedings of the National Academy of Sciences of the United States of America.
120(47)
[DOI] 10.1073/pnas.2305215120.
[PMID] 37972067.
2023
Argentatin C Analogues with Potential Antinociceptive Activity and Other Triterpenoid Constituents from the Aerial Parts of Parthenium incanum.
ACS omega.
8(22):20085-20095
[DOI] 10.1021/acsomega.3c02302.
[PMID] 37305315.
2023
Breast cancer therapies reduce risk of Alzheimer’s disease and promote estrogenic pathways and action in brain.
iScience.
26(11)
[DOI] 10.1016/j.isci.2023.108316.
[PMID] 38026173.
2023
Identification and targeting of a unique NaV1.7 domain driving chronic pain.
Proceedings of the National Academy of Sciences of the United States of America.
120(32)
[DOI] 10.1073/pnas.2217800120.
[PMID] 37498871.
2023
Targeting the vascular endothelial growth factor A/neuropilin 1 axis for relief of neuropathic pain.
Pain.
164(7):1473-1488
[DOI] 10.1097/j.pain.0000000000002850.
[PMID] 36729125.
2023
The natural product argentatin C attenuates postoperative pain via inhibition of voltage-gated sodium and T-type voltage-gated calcium channels.
British journal of pharmacology.
180(9):1267-1285
[DOI] 10.1111/bph.15974.
[PMID] 36245395.
2022
Stereospecific Effects of Benzimidazolonepiperidine Compounds on T-Type Ca2+ Channels and Pain.
ACS chemical neuroscience.
13(13):2035-2047
[DOI] 10.1021/acschemneuro.2c00256.
[PMID] 35671441.
2022
The small molecule compound C65780 alleviates pain by stabilizing voltage-gated sodium channels in the inactivated and slowly-recovering state.
Neuropharmacology.
212
[DOI] 10.1016/j.neuropharm.2022.109057.
[PMID] 35413303.
2021
Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells.
Stem cell reports.
16(10):2459-2472
[DOI] 10.1016/j.stemcr.2021.08.018.
[PMID] 34525378.
2021
Comparison of quinazoline and benzoylpyrazoline chemotypes targeting the CaVα-β interaction as antagonists of the N-type CaV2.2 channel.
Channels (Austin, Tex.).
15(1):128-135
[DOI] 10.1080/19336950.2020.1863595.
[PMID] 33416017.
2021
Novel Compounds Targeting Neuropilin Receptor 1 with Potential To Interfere with SARS-CoV-2 Virus Entry.
ACS chemical neuroscience.
12(8):1299-1312
[DOI] 10.1021/acschemneuro.0c00619.
[PMID] 33787218.
2021
SARS-CoV-2 spike protein co-opts VEGF-A/neuropilin-1 receptor signaling to induce analgesia.
Pain.
162(1):243-252
[DOI] 10.1097/j.pain.0000000000002097.
[PMID] 33009246.
2021
Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents.
Science translational medicine.
13(619)
[DOI] 10.1126/scitranslmed.abh1314.
[PMID] 34757807.
2020
A modulator of the low-voltage-activated T-type calcium channel that reverses HIV glycoprotein 120-, paclitaxel-, and spinal nerve ligation-induced peripheral neuropathies.
Pain.
161(11):2551-2570
[DOI] 10.1097/j.pain.0000000000001955.
[PMID] 32541387.
2020
Druggability of CRMP2 for Neurodegenerative Diseases.
ACS chemical neuroscience.
11(17):2492-2505
[DOI] 10.1021/acschemneuro.0c00307.
[PMID] 32693579.
2020
The role of cyclin-dependent kinase 5 in neuropathic pain.
Pain.
161(12):2674-2689
[DOI] 10.1097/j.pain.0000000000002027.
[PMID] 32773603.
2019
Small Molecule Targeting TDP-43’s RNA Recognition Motifs Reduces Locomotor Defects in a Drosophila Model of Amyotrophic Lateral Sclerosis (ALS).
ACS chemical biology.
14(9):2006-2013
[DOI] 10.1021/acschembio.9b00481.
[PMID] 31241884.
2019
Structural Insights Into TDP-43 and Effects of Post-translational Modifications.
Frontiers in molecular neuroscience.
12
[DOI] 10.3389/fnmol.2019.00301.
[PMID] 31920533.
2019
Targeting the CaVα-CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy.
Pain.
160(7):1644-1661
[DOI] 10.1097/j.pain.0000000000001524.
[PMID] 30933958.
2019
The Natural Flavonoid Naringenin Elicits Analgesia through Inhibition of NaV1.8 Voltage-Gated Sodium Channels.
ACS chemical neuroscience.
10(12):4834-4846
[DOI] 10.1021/acschemneuro.9b00547.
[PMID] 31697467.
2018
A Chemical Biology Approach to Model Pontocerebellar Hypoplasia Type 1B (PCH1B).
ACS chemical biology.
13(10):3000-3010
[DOI] 10.1021/acschembio.8b00745.
[PMID] 30141626.
2018
A novel variant in TAF1 affects gene expression and is associated with X-linked TAF1 intellectual disability syndrome.
Neuronal signaling.
2(3)
[DOI] 10.1042/NS20180141.
[PMID] 32714589.
2018
Chemical shift perturbation mapping of the Ubc9-CRMP2 interface identifies a pocket in CRMP2 amenable for allosteric modulation of Nav1.7 channels.
Channels (Austin, Tex.).
12(1):219-227
[DOI] 10.1080/19336950.2018.1491244.
[PMID] 30081699.
2018
Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2-derived peptides.
British journal of pharmacology.
175(12):2244-2260
[DOI] 10.1111/bph.13737.
[PMID] 28161890.
2018
Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain.
Pain.
159(10):2115-2127
[DOI] 10.1097/j.pain.0000000000001294.
[PMID] 29847471.
2017
A single structurally conserved SUMOylation site in CRMP2 controls NaV1.7 function.
Channels (Austin, Tex.).
11(4):316-328
[DOI] 10.1080/19336950.2017.1299838.
[PMID] 28277940.
2016
(S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5.
Molecular neurobiology.
53(3):1959-1976
[DOI] 10.1007/s12035-015-9141-2.
[PMID] 25846820.
2013
Catalytic contribution of threonine 244 in human ALDH2.
Chemico-biological interactions.
202(1-3):32-40
[DOI] 10.1016/j.cbi.2012.12.009.
[PMID] 23295226.
2013
Expression and purification of functional human glycogen synthase-1 (hGYS1) in insect cells.
Protein expression and purification.
90(2):78-83
[DOI] 10.1016/j.pep.2013.05.007.
[PMID] 23711380.
2011
Discovery of a novel class of covalent inhibitor for aldehyde dehydrogenases.
The Journal of biological chemistry.
286(50):43486-94
[DOI] 10.1074/jbc.M111.293597.
[PMID] 22021038.
2010
Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant.
Nature structural & molecular biology.
17(2):159-64
[DOI] 10.1038/nsmb.1737.
[PMID] 20062057.
2010
High resolution X-ray structures of mouse major urinary protein nasal isoform in complex with pheromones.
Protein science : a publication of the Protein Society.
19(8):1469-79
[DOI] 10.1002/pro.426.
[PMID] 20509168.
2007
Light chain C-terminal region reinforces the stability of clathrin heavy chain trimers.
Traffic (Copenhagen, Denmark).
8(8):1101-10
[PMID] 17555534.
2003
Coenzyme isomerization is integral to catalysis in aldehyde dehydrogenase.
Biochemistry.
42(23):7100-9
[PMID] 12795606.
2001
Order and disorder in mitochondrial aldehyde dehydrogenase.
Chemico-biological interactions.
130-132(1-3):3-14
[PMID] 11306026.
2001
Three-dimensional structures of the three human class I alcohol dehydrogenases.
Protein science : a publication of the Protein Society.
10(4):697-706
[PMID] 11274460.
Grants
Jan 2024
ACTIVE
Genetic and Pharmacological Validation of CRMP2 Phosphorylation as a Novel therapeutic Target for Neuropathic Pain
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Contact Details
Phones:
- Business:
- (352) 294-5350
Emails:
- Business:
- perezmiller.s@ufl.edu
Addresses:
- Business Street:
-
PO Box 100267
GAINESVILLE FL 32610